Vivek Kamath
Abstract
The International COPD market is consider being worth $9.9 billion presently, and is expected to bench a value of $14.1 billion by 2025. The drugs driving this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. The opportunity in the U.S. and China asthma and COPD drugs market is slated to rise from a valuation of US$13.0 billion in 2015 to be worth US$18.7 billion by 2024. If these values hold true, the market is likely to expand at a modest CAGR of 4.1% therein. North Hemisphere countries trends the international market for COPD drugs. And it was followed by the European countries market capitalization. The Asia Pacific region is forecast to be the rapid regional for COPD & Asthma market owing to the fastest frequency of asthma & other respiratory diseases in industrial region.